Dosage Protocol
GLP-3R
(Retatrutide)
20mg
CATEGORY: Weight loss I GLP-1/GIP/GCG
RECONSTITUTION PROTOCOL
-
Diluent Amount: 2ML Bacteriostatic Water
DOSAGE INSTRUCTIONS
• Suggested Dosage:
• (Start) Weeks 1-4: 1mg (10units), 3/week.
• (Maintenance) Week 5+: Titrate as needed by 0.5mg (5units per dose)
• Dosage Frequency: 3 times a week
• Route: Subcutaneous
• Cycle Duration: Maintenance as needed
​
​
For research or educational purposes only. Suggested protocol only, consume at own risk.Â
GLP-3R
(Retatrutide)
10mg
CATEGORY: Weight loss I GLP-1/GIP/GCG
RECONSTITUTION PROTOCOL
-
Diluent Amount: 1ML Bacteriostatic Water
DOSAGE INSTRUCTIONS
• Suggested Dosage:
• (Start) Weeks 1-4: 1mg (10units), 3/week.
• (Maintenance) Week 5+: Titrate as needed by 0.5mg (5units per dose)
• Dosage Frequency: 3 times a week
• Route: Subcutaneous
• Cycle Duration: Maintenance as needed
​
​
For research or educational purposes only. Suggested protocol only, consume at own risk.Â
GLP-3R
(Retatrutide)
5mg
CATEGORY: Weight loss I GLP-1/GIP/GCG
RECONSTITUTION PROTOCOL
-
Diluent Amount: 1ML Bacteriostatic Water
DOSAGE INSTRUCTIONS
• Suggested Dosage:
• (Start) Weeks 1-4: 1mg (20units), 3/week.
• (Maintenance) Week 5+: Titrate as needed by 0.5mg (10 units per dose)
• Dosage Frequency: 3 times a week
• Route: Subcutaneous
• Cycle Duration: Maintenance as needed
​
​
For research or educational purposes only. Suggested protocol only, consume at own risk.Â
Notes & Precautions
• Inject in PM, in fasted state (2 hrs after last meal), Titrate as needed
• Max dose is 15mg / week
• Injection site may be tender/ irritation after injection
• Stay hydrated
• May cause slight nausea
• It's important to eat an adequate amount of food, even though you may not be hungry
Description
GLP-3 R (Retatrutide) is a synthetic peptide analog designed for advanced biochemical and pharmacological research. It functions as a triple receptor agonist targeting GLP-1, GIP, and Glucagon receptors, making it an exciting compound for the exploration of metabolic and energy-balance pathways in preclinical settings.
​
Retatrutide works by enhancing satiety signals in the brain while simultaneously improving insulin sensitivity and promoting energy utilization. Activation of GLP-1 and GIP receptors helps slow gastric emptying and reduce food intake, while glucagon receptor stimulation increases energy expenditure and fat breakdown. This combined effect leads to significant reductions in body weight and improvements in metabolic markers such as blood glucose and lipid profiles. Because of its broad mechanism, Retatrutide is being studied as a next-generation therapy for obesity and related conditions, offering a more comprehensive approach to metabolic regulation.